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esponsibility of InstAbstract Considering that some antibacterial agents can identify the outer structure of pathogens like
cell wall and/or cell membrane, we explored a self-enhanced targeted delivery strategy by which a small
amount of the antibiotic molecules were modiﬁed on the surface of carriers as targeting ligands of certain
bacteria while more antibiotic molecules were loaded inside the carriers, and thus has the potential to
improve the drug concentration at the infection site, enhance efﬁcacy and reduce potential toxicity. In this
study, a novel targeted delivery system against methicillin-resistant Staphylococcus aureus (MRSA)
pneumonia was constructed with daptomycin, a lipopeptide antibiotic, which can bind to the cell wall of S.
aureus via its hydrophobic tail. Daptomycin was conjugated with N-hydroxysuccinimidyl–polyethylene
glycol–1,2-distearoyl-sn-glycero-3-phosphoethanolamine to synthesize a targeting compound (Dapt–
PEG–DSPE) which could be anchored on the surface of liposomes, while additional daptomycin
molecules were encapsulated inside the liposomes. These daptomycin-modiﬁed, daptomycin-loaded
liposomes (DPD-L[D]) showed speciﬁc binding to MRSA as detected by ﬂow cytometry and good
targeting capabilities in vivo to MRSA-infected lungs in a pneumonia model. DPD-L[D] exhibited more
favorable antibacterial efﬁcacy against MRSA than conventional PEGylated liposomal daptomycin both
in vitro and in vivo. Our study demonstrates that daptomycin-modiﬁed liposomes can enhance MRSA-
targeted delivery of encapsulated antibiotic, suggesting a novel drug delivery approach for existing
antimicrobial agents.
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“Magic bullets”, put forward by Paul Ehrlich, was ﬁrst used to refer to
compounds that had special afﬁnity for pathogens and destructive
power over them1. This concept has led to the development of a
number of nano-sized drug carriers modiﬁed by targeting ligands,
referred to as “active targeting drug delivery systems” and widely used
in tumor therapy. Considering the increasing difﬁculties in developing
new antibacterial agents and the limitations of the existing antibiotics,
including toxicity to normal tissues, drug resistance, and rapid degra-
dation and clearance, novel drug delivery approaches are urgently
required to address these problems. Unlike the relatively high similarity
between cancer cells and normal tissue cells, there are huge differences
between prokaryotic cells (pathogens) and eukaryotic cells (hosts),
especially the outer part of bacteria providing an “Achilles' Heel” for
recognition and tracking. By attaching a targeting moiety such as an
antibody, an aptamer or peptides to the surface of a nano-carrier, these
drug delivery agents can selectively bind to microorganisms or infected
cells and release drug payloads to kill or inhibit the growth of the
microorganisms, thereby signiﬁcantly enhancing the therapeutic efﬁ-
cacy of existing antimicrobial therapies2. However, the current used
ligands for targeting pathogen is very limited, with some suffereing
from in vivo stability and high cost, which necessitates the design or
development of new ligands.
It is worth noting that there are many antimicrobial agents that target
the bacterial cell wall and/or cell membrane. For some of them
corresponding targets exist on the surface of bacterial cells allowing
speciﬁc binding. There is a possibility, therefore, that those cell wall–
and membrane-active agents may work as targeting molecules for
bacteria rather than as a direct inhibitor when used at a very low dose.
For example, vancomycin, a glycopeptide antibiotic which can bind to
Gram-positive bacteria via a ﬁve-point hydrogen bond interaction with
the D-Ala–D-Ala moieties of N-acetylmuramic acid and N-acetylglu-
cosamine peptide subunits in the cell wall, was used as a molecular
recognition agent for Staphylococcus aureus in vitro3. UBI29-41, a
human antimicrobial peptide fragment, was conjugated to chloram-
phenicol for the targeted therapy of bacterial infections4. These ﬁndings
suggest that some antibiotic agents may have potential to be targeting
ligands of pathogens, in addition to their anti-bacterial properties.
Daptomycin, a novel cyclic lipopeptide antibiotic, has been proven
to be a successful and less toxic alternative to vancomycin in the
treatment of multidrug resistant Gram-positive pathogens5. It has a
unique chemical structure containing a 13-member amino acid cyclic
lipopeptide (hydrophilic core) with a decanoyl side chain (lipophilic
tail). Daptomycin exerts its antibacterial effect via binding to the cell
wall of Gram-positive bacteria, resulting in perturbation and depolar-
ization of the cell membrane6. Currently, Cubicins, an injectable
solution, is the only approved formulation of daptomycin. Therefore,
there is a growing interest in the development of new formulations and
delivery methods to further enhance the in vivo performance of
daptomycin7,8.
Liposomes as nano-carriers have been widely used for antimicrobial
drug delivery, including polymyxin B liposomes9, benzyl penicillin
liposomes10 and teicoplanin liposomes11. Liposomes can encapsulate
both hydrophilic and hydrophobic compounds, increasing the drug
solubility. They provide better pharmacokinetics and biodistribution
versus nonencapsulated drug, and enhance activity against both
extracellular and intracellular pathogens12. Conventional liposomes
can be further designed with active targeting property by surface
modiﬁcation to better target and selectively bind to microorganisms,
and thereby improve drug accumulation at the infected sites, reduce
adverse effects, decrease drug toxicity, and increase efﬁcacy.Herein, we propose a self-enhanced targeted delivery strategy:
daptomycin molecules, modiﬁed as targeting molecules by
conjugation with N-Hydroxysuccinimidyl (NHS)–polyethylene
glycol (MW3400 Da, PEG3400)–1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine (DSPE), were modiﬁed and placed on the
surface of liposomes in which more daptomycin molecules were
encapsulated. The methicillin-resistant S. aureus (MRSA) binding
capability of these daptomycin-modiﬁed liposomes was measured
in vitro. Mouse models of MRSA hematogenous pulmonary
infection were used to further evaluate the targeting efﬁcacy and
curative effects in vivo.2. Materials and methods
2.1. Materials
Daptomycin was purchased from Meilun Biotech Co. (Dalian,
China). NHS–PEG3400–DSPE was supplied by Nanocs Corp.
(New York, NY, USA). Soybean phospholipids (SPC) were from
Aladdin Bio-Chem Technology Co., Ltd. (Shanghai, China). m-
Polyethylene glycol2000 (mPEG2000)–DSPE was obtained from
AVT pharmaceuticals Co., Ltd. (Shanghai, China). 1,10-Dioctade-
cyl-3,3,3,3-tetramethylindotricarbocyanineiodide (DiR) was sup-
plied by Invitrogen Corp. (Life Technologies, Carlsbad, CA,
USA). Fluoresceinamine isomer II (FAM) was from Sigma-
Aldrich (St. Louis, MO, USA). The other reagents were all of
analytical grade.
MRSA252 was incubated in tryptic soy broth (Nissui Pharma-
ceuticals, Japan) at 37 1C. Six-week-old male/female Kunming
(KM) mice weighing 2072 g were purchased from the experi-
mental animal center of Third Military Medical University
(Chongqing, China) and kept in regulated conditions. All animal
experiments were performed in accordance with the guidelines
approved by the ethics committee of the College of Pharmaceutical
Sciences, Southwest University, China.
2.2. Targeting compound synthesis and characterization
For the synthesis of the targeting compound Dapt–PEG–DSPE,
daptomycin was conjugated with NHS–PEG3400–DSPE by an
amide reaction13. Daptomycin and NHS–PEG3400–DSPE were
dissolved in newly distilled dimethyl fumarate (DMF) at a molar
ratio of 1.2:1 and the pH of the solution was adjusted to 8.0–8.5
with an appropriate amount of triethylamine, followed by stirring
continuously for 72 h at 25 1C. The reaction endpoint was
conﬁrmed by HPLC and the product was puriﬁed by dialysis
(MW cut off 3500 Da) against distilled water for 48 h. Finally, the
product solution was lyophilized. To conﬁrm the conjugation of
daptomycin with NHS–PEG3400–DSPE, the ﬁnal product was
assayed by a matrix-assisted laser desorption/ionization time-of-
ﬂight MS (MALDI-TOF-MS, Autoﬂex speed, Bruker, Germany).
2.3. Preparation of liposomes
Daptomycin-loaded liposomes modiﬁed by Dapt–PEG–DSPE (DPD-L
[D]) were prepared by a thin-ﬁlm hydration method. Brieﬂy, SPC:chol-
esterol:mPEG2000–DSPE:Dapt–PEG–DSPE (73.5:24.5:1.5:0.5, molar
ratio) was dissolved in methanol. To form a lipid ﬁlm, the mixture was
evaporated to remove methanol and mixed with physiological saline
containing daptomycin (drug:lipids¼1:10, w/w) and sonicated. The
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were puriﬁed by Sepharose CL-4B chromatography to remove free
drug. PEGylated liposomal daptomycin (mPEG-L[D], SPC:
cholesterol:mPEG2000–DSPE¼73.5:24.5:2, molar ratio; daptomycin:
lipids¼1:10, w/w) and Dapt–PEG–DSPE-modiﬁed blank liposomes
(DPD-Lip; SPC:cholesterol:mPEG2000–DSPE:Dapt–PEG–DSPE¼
73.5:24.5:1.5:0.5, molar ratio) were prepared by the same method as
DPD-L[D].
A preparation of liposomes loading with ﬂuorescent reagents
was prepared following a procedure identical to that used for Dapt-
loaded liposomes, with daptomycin replaced by FAM dispersed in
solution or by DiR dissolved in methanol, respectively.
2.4. Characterization of liposomes
The particle size and polydispersity index of the liposomes was
measured by dynamic light scattering using a Zetasizer Nano ZS
(Malvern, Worcestershire, UK). The entrapment efﬁciency of
DPD-L[D] was determined by gel ﬁltration. The crude liposomes
prior to chromatographic puriﬁcation were divided into two equal
parts. One part was puriﬁed using the Sephadex CL-4B column
and the eluent collected. The other was diluted into the same
volume of the eluent above. The two samples were then treated
with 10% (v/v) Triton X-100 for demulsiﬁcation. Encapsulation
efﬁciency (EE) was calculated as follows: EE (%)¼ (W/W0) 100,
where W and W0 are the daptomycin content in puriﬁed liposomes
and total drug in dispersion, respectively. The content of
daptomycin was measured by high performance liquid chromato-
graphy (HPLC).
2.5. Determination of the minimum inhibitory concentration
(MIC)
The MIC of DPD-L[D], mPEG-L[D], and free daptomycin were
determined by the broth micro-dilution method in 96-well plates14.
Since daptomycin is a calcium-dependent antibiotic, the MICs
were measured by using Mueller–Hinton II broth with 50 μg/mL
calcium ions15. Each preparation was added to 100 μL Mueller–
Hinton II broth at sequential 2-fold dilutions, with concentrations
in the range of 64–0.0625 μg/mL. A 100 μL MRSA252 aliquot
(106 CFU/mL) was added to each well. The plates were incubated
at 37 1C for 24 h. The MIC was designated as the lowest
concentration of daptomycin at which there was no visible and
measurable MRSA growth after 24 h of incubation. Each experi-
ment was performed in triplicate.
2.6. In vitro targeting efﬁcacy
Flow cytometry (ACEA Novo Cyte, 2060R, Shanghai, China) was
used to measure the speciﬁc binding between Dapt–PEG–DSPE-
modiﬁed FAM-loaded liposomes (DPD-L[FAM]) and bacteria.
PEGylated liposomal FAM (mPEG-L[FAM]) and free FAM to
MRSA252 were also evaluated in parallel. The mixture of DPD-
Lip (Dapt–PEG–DSPE-modiﬁed blank liposome) and free FAM
were used as controls. MRSA252 was incubated in Mueller-
Hinton II broth with shaking overnight to logarithmic phase
growth at 37 1C. Bacteria were collected by centrifugation at
3000 g for 10 min and resuspended in fresh medium to the
desired density (108 CFU/mL). FAM-loaded liposomes were
mixed with bacterial suspension at a 1:9 (v/v) ratio and incubated
at 37 1C for 1 and 2 h. Samples then were centrifuged (3000 g,10 min) to collect the bacterial cells and rinsed with PBS 3 times,
then measured by ﬂow cytometry. The bacterial suspension served
as a blank control. The velocity of ﬂow was 14 μL/min, and the
diameter of the sample ﬂow oriﬁce was 7.7 μm. Bacterially-
associated FAM was excited with an argon laser (488 nm), and
ﬂuorescence was detected at 530 nm.
2.7. Establishment and evaluation of MRSA252 hematogenous
pneumonia model
Animal models were established by the method previously
reported16,17. Brieﬂy, MRSA252 in the logarithmic phase were
collected by centrifugation at 3000 g for 10 min and resus-
pended in sterilized normal saline and washed three times.
Subsequently, the suspension was warmed to 45 1C. The bacterial
suspension was mixed with 4% (w/v) molten agar in the proportion
of 1:1 at 45 1C. One milliliter of the agar-bacterium suspension
was rapidly injected into 49 mL of rapidly stirred ice-bath-chilled
sterile saline via a 1 mL syringe with 26-gauge needle, and agar
beads formed. The ﬁnal concentration of agar was 0.04% (w/v),
and the ﬁnal number of bacteria was 2 109 CFU/mL.
A murine model of hematogenous pneumonia infection was
generated by injecting 250 μL suspension containing bacteria-loaded
agar beads into the tail vein of KM mice. As a contrast, 250 μL
bacteria suspension (2×109 CFU/mL) was injected. Six infected mice
in each group were killed to get lung, liver, kidney and spleen under
aseptic conditions at 1, 3 and 7 days post-injection. The tissue was
weighed and homogenized for bacteria counts, suspended in sterile
saline and cultured quantitatively by serial dilutions on MH IIA plates
at 37 1C. The number of colony forming units (CFU) was counted
24 h later.
2.8. In vivo optical imaging
Mice (normal or pneumonic) were intravenously administered
Dapt–PEG–DSPE-modiﬁed DiR-loaded liposomes (DPD-L[DiR])
or PEGylated liposomal DiR (mPEG-L[DiR]). To detect DiR
ﬂuorescence, an in vivo imaging system (FX-Pro, BRUKER) with
a 730 nm excitation ﬁlter and an emission ﬁlter at 790 nm were
used. Hair was removed from the mice using 8% (w/v) sodium
sulﬁde solution. Mice were scanned at 2, 4, 8 and 12 h. Mean-
while, different organs (heart, liver, spleen, lung, kidney and brain)
were removed for ex vivo imaging.
2.9. Biodistribution study
Seventy-two KM-infected mice were randomly assigned to three
groups: treated with DPD-L[D], mPEG-L[D], or free daptomycin
via intravenous administration. The dosage in each group was
equivalent to a 25 mg/kg dose of daptomycin. The mice were
killed with removal of liver, spleen, lung and kidney at prede-
termined time intervals (0.5, 4, 8 and 24 h). The tissues were
weighed and homogenized in physiological saline. Daptomycin
was extracted from the tissue samples by a mixed solvent of
acetonitrile and methanol (1:1, v/v). The supernatant was trans-
ferred and then dried by a stream of nitrogen gas. The residue was
redissolved in ultrapure water and further analyzed by HPLC. For
HPLC detection of daptomycin, the mobile phase was composed
of acetonitrile and 0.5% NH4H2PO4 at a volume ratio of 40:60.
The mobile phase was delivered at a ﬂow rate of 0.7 mL/min and
kept at 30 1C. Column eluate was monitored at 221 nm.
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This study included ﬁve groups: three treatment groups with 30
pneumonic mice (n¼10 per group) with each group receiving a
single dose treatment via tail vein with one of the preparations:
DPD-L[D], mPEG-L[D] and saline. The dosage of DPD-L[D] or
mPEG-L[D] was equivalent to a 25 mg/kg dose of daptomycin
which is only half of the reported dosage18. Herein, Dapt–PEG–
DSPE was calculated as an equivalent amount of daptomycin in
the preparation of DPD-L[D]. Meanwhile, normal mice received
an injection in the tail vein of either saline or a suspension
containing agar beads without bacteria. The survival rate of the
mice and body weight changes were monitored for 10 days. Lung
samples were obtained from pneumonic mice administered DPD-L
[D], mPEG-L[D] or saline at the 3rd day post-injection for
histopathological evaluation and bacterial number counts.
A preliminary safety assessment of the daptomycin-loaded
liposomes treatment was conducted via studying serum biochem-
ical parameters, including alanine aminotransferase, aspartate
aminotransferase, blood urea nitrogen, creatinine phosphokinase,
creatinine and uric acid, using a fully automated biochemistry
analyser (TMS-1024i, BOEKI, Japan).2.11. Data analysis
Survival data are presented using Kaplan–Meier plots and were
analyzed using a log-rank test. Student's t-test was employed forScheme 1 Model for the synthesi
Figure 1 The MALDI-TOF mass spectrometry analysis of Dapt–PEG–D
corresponding to the targeting compound. The molecular weight of DPDcomparing two groups, and the one-way analysis of variance
(ANOVA) was used for multiple group comparisons. A value of
Po0.05 was considered statistically signiﬁcant.3. Results and discussion
3.1. Preparation and characterization of liposomes
The hydrophilic core of daptomycin contains an active amino
group that can react with succinimide, so the targeting compound
can be synthesized by conjugation of daptomycin (MW
1620.68 Da) with NHS–PEG3400–DSPE in DMF through a
nucleophilic substitution reaction which forms the amide bond19
(Scheme 1). As shown in Fig. 1, the experimental MW of
NHS–PEG3400–DSPE and Dapt–PEG–DSPE determined by
MALDI-TOF-MS were around 3700 and 5300 Da, respectively.
These values were in accordance with the theoretical MW and
conﬁrmed the identity of the synthesis product.
Since S. aureus ranges from 0.9–1.6 mm in diameter20, much
smaller than eukaryotic cells, control of the liposomal particle size
may be necessary. The characteristics of liposomes modiﬁed with
Dapt–PEG–DSPE or mPEG–DSPE are summarized in Table 1. As
shown, all liposomes had a uniform particle size less than 100 nm,
with a narrow distribution. Approximately 90% of the daptomycin
can be loaded into liposomes. In addition, the stability of drug-
loaded liposomes was evaluated at 25 1C. There were no obviouss of Dapt–PEG–DSPE (DPD).
SPE (DPD) and NHS–PEG3400–DSPE. The arrow indicates the peak
was approximately 5300 Da.
Table 1 Characterization of liposomes.
Liposomes Z-average
(nm)
PDI Entrapment
efﬁciency
(%)
DPD-L[D] 94.6071.12 0.2470.12 91.8572.16
mPEG-L[D] 93.8872.15 0.2270.08 93.7371.47
DPD-L[FAM] 91.4172.02 0.2270.06 27.5671.06
mPEG-L[FAM] 90.2371.42 0.2670.09 28.2170.63
DPD-L[DiR] 88.2571.33 0.2170.05 88.7972.06
mPEG-L[DiR] 86.7270.95 0.1970.03 90.2171.54
Data are expressed as mean7SD, n¼3.
Table 2 Stability evaluation of DPD-L[D] at 2570.3 1C.
Time (day) Z-average (nm) PDI Drug leakage (%)
0 94.6071.12 0.2470.12 –a
7 93.9271.91 0.2570.08 0.3570.13
15 98.2472.73 0.2970.02 0.6070.21
30 100.7972.38 0.3270.06 1.4570.16
Data are expressed as mean7SD, n ¼ 3.
aNot applicable.
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(Table 2).3.2. In vitro MRSA targeting and pharmacodynamics
The uptake of Dapt–PEG–DSPE-modiﬁed liposomes by MRSA
was detected by ﬂow cytometry, and water-soluble FAM served as
ﬂuorescence probe (Fig. 2). There was a signiﬁcant difference in
ﬂuorescence intensity between the DPD-L[FAM] group and that of
mPEG-L[FAM] group, the former was 3.30- and 3.44-fold higher
than the latter after incubation for 1 and 2 h, respectively. No
obvious increase in ﬂuorescence signal was observed in theFigure 2 Flow cytometric measurement of the interaction oftreatment group by the physical mixture of DPD-Lip and FAM
when compared with that of mPEG-L[FAM] group, supporting the
potential of daptomycin as a targeting ligand to mediate liposomal
drug delivery to the targeted bacteria.
The broth micro-dilution method was used to determine the
MIC of each formulation. The results showed MICs of free
daptomycin, mPEG-L[D] and DPD-L[D] against MRSA252 of
0.5, 0.5, and 0.25 μg/mL, respectively. It is worth noting that
Dapt–PEG–DSPE was calculated as an equivalent amount of
daptomycin in the preparation of DPD-L[D]. Therefore, the above
results primarily illustrate that the placement of a fraction of
daptomycin on the surface enhanced the anti-bacterial efﬁcacy of
liposomal daptomycin.3.3. Establishment of S. aureus hematogenous pneumonia model
In this study, pneumonia models were constructed via intravenous
administration of bacteria embedded in agar beads18. It is well
accepted that larger microspheres (greater than 20 μm) will be
effectively accumulated in lung via the mechanical trapping effect
of pulmonary capillaries after intravenous injection21. Accord-
ingly, it can be expected that bacteria-loaded agar beads in the
micrometer range may be concentrated in lung leading to
pneumonia. We also have established an animal model simply
by giving a bacterial suspension prepared in saline for comparison,
and time-dependent changes in the number of viable MRSA252 in
the major organs are shown in Fig. 3. The mice injected with
MRSA252 enmeshed in agar beads is designated group A, and the
mice infected by a bacterial suspension designated group N. The
bacterial number in the lungs was markedly higher than that of
other organs in group A (Fig. 3A) 1, 3 or 7 days post-infection
(Po0.01) and was more than 10-fold higher than that in the livers.
There were no marked differences in the bacterial numbers
between the lung, liver and kidneys of group N (Fig. 3B). These
ﬁndings indicate that the bacteria-loaded agar bead technique
increased infection efﬁciency and selectivity to lung, conﬁrming
that a murine model of hematogenous pneumonia infection has
been established.bacteria with different formulations at 1 h (A) and 2 h (B).
Figure 3 The bacterial loads in the major organs of pneumonia-model mice established by different approach. The mice were injected with
MRSA252 enmeshed in agar beads (A) or infected by bacteria suspension (B). Data are expressed as mean7SD, n¼6.
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Both the pneumonia model and normal mice were used in the
in vivo imaging assays. As shown in Figs. 4 and 5, daptomycin-
modiﬁed liposomes markedly increased the distribution of encap-
sulated ﬂuorophore in infected lung compared with non-modiﬁed
liposomes at each time point. However, in the treatment groups of
normal mice there were no differences observed between those
treated with daptomycin-modiﬁed liposomes and non-modiﬁed
liposomes, indicating that speciﬁc interactions between daptomy-
cin and MRSA were mainly responsible for the lung targeting of
the liposomes. Furthermore, a quantitative analysis of drug
distribution in multiple organs was performed after a single dose
of 25 mg/kg of encapsulated daptomycin in bacterially infected
mice (Fig. 6). It is clearly shown that the daptomycin concentra-
tion of lung tissues in the DPD-L[D] group were markedly higher
than those in the mPEG-L[D] group and the free daptomycin
injection group. Previously we have reported that conventional
daptomycin-loaded liposomes increased level of daptomycin in the
lung tissue of infected mice22, and here the further modiﬁcation of
liposomes by daptomycin itself has made a further improvement in
the targeting efﬁciency.Figure 4 In vivo whole-body ﬂuorescence imaging in mice administered
12 h (D): normal mice treated by DPD-L[DiR] (a), infected mice by DPD
mPEG-L[DiR] (d).3.5. In vivo anti-infective efﬁcacy
In comparison, the survival rates (Fig. 7A) of animals treated with
DPD-L[D] or mPEG-L[D] were 60% and 40% at the 10th day,
respectively. Obviously, the survival period of the DPD-L[D]
group was signiﬁcantly prolonged (Po0.05) compared to that of
mPEG-L[D] group. Meanwhile, the mortality rate of the untreated
group approached 100% by the 8th day post-administration.
Normal mice given 0.04% agar beads or saline served as controls.
As Fig. 7B shows, the body weight of the DPD-L[D], mPEG-L[D]
and untreated groups showed a downward trend within the ﬁrst
week, especially the latter group, mainly due to the low dosage of
daptomycin. However, the body weight of the DPD-L[D] group
decreased more slowly than the other infected groups and
increased gradually from the 8th day. An overall increase in body
weight was observed in the two groups of normal mice. The
bacteria present in the lung tissues of each group were counted on
the third day post-treatment. As shown in Fig. 8, the concentration
of bacteria in the DPD-L[D] treated group was almost three orders
of magnitude lower than that of untreated group and more than one
order of magnitude lower than that of the mPEG-L[D]
treated group.DiR-loaded formulations via tail vein at 2 h (A), 4 h (B), 8 h (C) and
-L[DiR] (b), infected mice by mPEG-L[DiR] (c), and normal mice by
Figure 5 Ex vivo ﬂuorescent images of tissues dissected from mice (A) and the semi-quantitative analysis (B): normal mice treated by DPD-L
[DiR] (a), infected mice by DPD-L[DiR] (b), infected mice by mPEG-L[DiR] (c) and normal mice by mPEG-L[DiR] (d).
Figure 6 Biodistribution of daptomycin in lungs (A), livers (B), spleens (C) and kidneys (D) following tail vein injection of a dose (25 mg/kg) of
DPD-L[D], mPEG-L[D] or free daptomycin in infected mice. All values are expressed as mean7SD (n ¼ 6). *Po0.05, **Po0.01.
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Figure 7 Antibacterial effect of drug treatments on pneumonia-infected mice. Survival rate (A) and body weight (B) changes. DPD-L[D]:
infected mice treated with DPD-L[D]; mPEG-L[D]: infected mice treated with mPEG-L[D]; blank: infected mice without treatment; agar: normal
mice treated with agar bead suspension; saline: normal mice treated with physiological saline. The DPD-L[D] and mPEG-L[D] groups received a
single dose of daptomycin (25 mg/kg). Data represented as mean 7SD (n ¼ 10). *P o 0.05.
Figure 8 Bacterial loads in lung tissues 3 days after intravenous tail
injection of a dose (25 mg/kg) of DPD-L[D] or mPEG-L[D] formula-
tions. Saline was used for the untreated group. Data represented as
mean7SD (n ¼ 6). *Po0.05, **Po0.01.
Figure 9 The histopathological examination of the major organs (lung and
received a single dose of daptomycin (25 mg/kg). Lung (H&E, 400 ):
thickening; ( ) indicates neutrophils; ( ) indicates eosinophils; ( ) in
degeneration and edema; ( ) indicates Kupffer cells; ( ) indicates inﬁltr
Hong Jiang et al.326Histopathological assessments were performed on the 3rd day
post-administration, as shown in Fig. 9. Lesions in liver and lung
in the DPD-L[D] group were lighter than that in mPEG-L[D]
group and untreated group. No signiﬁcant difference was observed
in serum biochemical parameters of all treatment groups compared
with those of the saline group (Fig. 10). These results further
demonstrate that DPD-L[D] had a much better antibacterial effect
than the conventional liposomal formulation when given the same
low dose of daptomycin.4. Conclusions
In summary, we have demonstrated the self-enhanced targeted
delivery of daptomycin against staphylococcal pneumonia, in
which daptomycin has dual function of both an MRSA-targeting
ligand and an antibiotic agent. This novel daptomycin-liposomal
formulation exhibited highly speciﬁc targeting and promisingliver) 3 days post-treatment. Both DPD-L[D] and mPEG-L[D] groups
( ) indicates alveolar atrophy or not expansion and alveolar wall
dicates dust cells. Liver (H&E 400 ): ( ) indicates cell granular
ation of inﬂammatory cells including lymphocytes and neutrophils.
Figure 10 Daily serum biochemical parameters detected during safety evaluation of daptomycin-modiﬁed daptomycin-loaded liposomes.
Alanine aminotransferase (A), aspartate aminotransferase (B), urea nitrogen (C), creatinine phosphokinase (D), creatinine (E) and uric acid
(F) levels from normal mice were detected on days 1, 0, 1, 3 and 7. Mice from saline group, DPD-L[D] group and mPEG-L[D] group were
administrated a dose of saline, daptomycin-modiﬁed daptomycin-loaded liposomes (mPEG-L[D] 25 mg/kg in a single i.v. dose), and PEGylated
liposomal daptomycin (mPEG-L[D], 25 mg/kg in a single i.v. dose) on day 0, respectively. Each data point represents the mean7SD, n¼6.
Self-enhanced targeted delivery of daptomycin 327therapeutic efﬁcacy against MRSA, both in vitro and in vivo. In
future research this self-enhanced targeting strategy can be
extended to other cell wall–/membrane-active antimicrobial agents,
creating innovative targeted therapeutic approaches against dan-
gerous pathogens.Acknowledgments
This study was supported by the National Natural Science
Foundation of China (No. 81102404), the Fundamental Research
Funds for the Central Universities (Nos. XDJK2015A012 and
XDJK2013A015), and the Program for Innovative Research Team
in University of Chongqing.References
1. Lagord C, Kearins O, Lawrence G, Bishop H, Monypenny I, Bates
AT. Paul Ehrlich: from magic bullets to chemotherapy. Colomb Med́
2008;39:291–5.
2. Zhang L, Pornpattananangku DC, Hu CM, Huang CM. Development
of nanoparticles for antimicrobial drug delivery. Curr Med Chem
2010;17:585–94.
3. Gao HF, Yang SJ, Han J, Xiong J, Kong WJ, Li C, et al. Double-site
recognition of pathogenic bacterium whole cells based on antibiotic-
afﬁnity strategy. Chem Commun 2015;51:12497–500.
4. Chen HY, Liu CC, Chen D, Madrid K, Peng SW, Dong XY, et al.
Bacteria-targeting conjugates based on antimicrobial peptide for
bacteria diagnosis and therapy. Mol Pharm 2015;12:2505–16.
5. Beiras-Fernandez A, Vogt F, Sodian R, Weis F. Daptomycin: a novel
lipopeptide antibiotic against Gram-positive pathogens. Infect Drug
Resist 2010;3:95–101.
Hong Jiang et al.3286. Steenbergen JN, Jeff A, Thorne GM, Tally FP. Daptomycin: a
lipopeptide antibiotic for the treatment of serious Gram-positive
infections. J Antimicrob Chemother 2005;55:283–8.
7. Zhang XL, Huang XL, Deng L, Li C, Liao GJ, Chen ZB. Preparation
and quality analysis of daptomycin transdermal delivery system. Chin
J Antibiot 2013;38:130–4.
8. Costa JR, Silva NC, Sarmento B, Pintado M. Potential chitosan-coated
alginate nanoparticles for ocular delivery of daptomycin. Eur J Clin
Microbiol Infect Dis 2015;34:1255–62.
9. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphoter-
icin B): a comparative review. J Clin Pharmacol 1998;38:583–92.
10. Kim HJ, Jones MN. The delivery of benzyl penicillin to Staphylo-
coccus aureus bioﬁlms by use of liposomes. J Liposome Res
2004;14:123–39.
11. Onyeji CO, Nightingale CH, Marangos MN. Enhanced killing of
methicillin-resistant Staphylococcus aureus in human macrophages by
liposome-entrapped vancomycin and teicoplanin. Infection
1994;22:338–42.
12. Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems
for antibiotics. Int J Pharm 2010;387:187–98.
13. Wang ZH, Yu Y, Dai WB, Lu JK, Cui JR, Wu HN, et al. The use of a
tumor metastasis targeting peptide to deliver doxorubicin-containing
liposomes to highly metastatic cancer. Biomaterials 2012;33:8451–60.
14. European Committee for Antimicrobial Susceptibility Testing
(EUCAST) of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID). Determination of minimum inhibitory
concentrations (MICs) of antibacterial agents by broth dilution. Clin
Microbiol Infect 2003;9:ix–xv.
15. Lai CC, Sheng WH, Wang JT, Liao CH, Ho MW, Chen CJ, et al.
Safety and efﬁcacy of daptomycin for the treatment of hospitalizedadult patients in Taiwan with severe staphylococcal infections. J
Microbiol Immunol Infect 2012;45:52–7.
16. Sawai T, Tomono K, Yanagihara K, Yamamoto Y, Kaku M, Hirakata
Y, et al. Role of coagulase in a murine model of hematogenous
pulmonary infection by intravenous injection of Staphylococcus
aureus enmeshed in agar beads. Infect Immun 1997;65:466–71.
17. Kihara R, Yanagihara K, Morinaga Y, Araki N, Nakamura S, Seki M,
et al. Potency of SMP-601, a novel carbapenem, in hematogenous
murine bronchopneumonia caused by methicillin-resistant and
vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents
Chemother 2008;52:2163–8.
18. Harada Y, Yanagihara K, Yamada K, Migiyama Y, Nagaoka K,
Morinaga Y, et al. In vivo efﬁcacy of daptomycin against
methicillin-resistant Staphylococcus aureus in a mouse model of
hematogenous pulmonary infection. Antimicrob Agents Chemother
2013;57:2841–4.
19. Chung HJ, Reiner T, Budin G, Min C, Liong M, Issadore D, et al.
Ubiquitous detection of Gram-positive bacteria with bioorthogonal
magnetoﬂuorescent nanoparticles. ACS Nano 2011;5:8834–41.
20. Lorian V, Zak O, Suter J, Bruecher C. Staphylococci, in vitro and
in vivo. Diagn Microbiol Infect Dis 1985;3:433–44.
21. Orson FM, Kinsey BM, Hua PJ, Bhogal BS, Densmore CL, Barry
MA. Genetic immunization with lung-targeting macroaggregated
polyethyleneimine-albumin conjugates elicits combined systemic and
mucosal immune responses. J Immunol 2000;164:6313–21.
22. Huang XL, Wu J, Su TT, Li YH, Chen ZB, Li C. Long-circulating
liposomal daptomycin enhances protection against systemic
methicillin-resistant Staphylococcus aureus infection with improved
therapeutic potential. Acta Pharm Sin 2014;49:701–10.
